Our website uses cookies to improve your experience. To make optimal use of this website please agree to our cookie policy.

I agree I do not agree.

Capacity building of a compound screening facility for Cuban-developed bioactive compounds targeting cell death and inflammation


Cell death is a crucial process in development, homeostasis and (patho)physiology. Most of high rate morbi-mortality diseases in Cuba like cancer and neurodegenerative diseases are associated with a deregulated balance between cell death and cell survival. Cuba offers an abundant source of natural and synthetic candidate drugs with potential effects relevant for the above mentioned diseases. However, infrastructure and know-how for experimental and preclinical evaluation of these drugs in valid cell-based models is lacking in Cuba, preventing further development of local potential drugs. This TEAM proposal aims at: 1) implementation of a methodological platform (knowledge and infrastructure currently lacking) in Cuba for the study of cell death mechanism and inflammation; 2) training of Cuban researchers in molecular mechanisms of cell death and inflammation, and especially in the preclinical evaluation of compound efficacy in relevant experimental disease models; 3) obtaining preclinical evidence for the molecular mechanism of action of novel drugs obtained in Cuba as proof-of-concept.

Intervention type

TEAM projects


01/01/2018 - 31/12/2021

This project is being implemented in:
Flemish promoter Peter Vandenabeele
Local promoter Gilberto Pardo Andreu
Local partner institution Universiteit Gent
visit www.ugent.be
Local partner institution Universidad de La Habana
visit http://www.uh.cu/
Other Flemish Partners Universiteit Antwerpen
visit www.uantwerpen.be
Other local partners Centro de Investigación y Desarrollo de Medicamentos
Budget € 279.627